Pembrolizumab in non-small cell lung cancer: Hint of considerable added benefit
In non-small cell lung cancer (NSCLC) that has already formed metastases, the suitable treatment depends, among other factors, on the genes that are activated in the tumour cells and whether mutations have occurred that make ...
May 15, 2017
0
0